Last reviewed · How we verify
VAD044 Part I
At a glance
| Generic name | VAD044 Part I |
|---|---|
| Also known as | VAD044 L-Tartrate gelatin capsules |
| Sponsor | Vaderis Therapeutics AG |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Assess Safety and Efficacy of VAD044 in HHT Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VAD044 Part I CI brief — competitive landscape report
- VAD044 Part I updates RSS · CI watch RSS
- Vaderis Therapeutics AG portfolio CI